2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Endothelial Dysfunction, Increased Arterial Stiffness, and Cardiovascular Risk Prediction in Patients With Coronary Artery Disease: FMD‐J (Flow‐Mediated Dilation Japan) Study A

“…For asymptomatic patients without a history of atherosclerotic cardiovascular disease (ASCVD), risk stratification tools have been developed and validated to provide the foundation for targeted preventive efforts based on the individual's predicted risk with the concept of targeting the intensity of drug treatment interventions to the severity of the patient's cardiovascular risk 22, 23, 24, 25. On the other hand, patients with ASCVD have been referred to as high‐risk patients for whom prompt initiation of guideline‐recommended therapies should be considered to reduce the risk.…”

Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid‐Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease

“…US guidelines recommend using the maximum tolerated statin dose with consideration given to the addition of a nonstatin cholesterol‐lowering drug if the clinical benefit outweighs the safety risk in these patients 16. Trials that evaluate the lipid‐lowering efficacy of different modes of therapy may provide helpful information for physicians when considering therapeutic options for high‐risk patients on statin therapy in need of additional LDL‐C lowering.…”

International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post‐MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee

“…Therefore, TRS2°P seems particularly useful in stratifying patients into risk categories (as shown in Figure 3) rather than predicting the absolute risk of having an adverse outcome. Nonetheless, unlike primary prevention therapy (eg, statin therapy in 10‐year risk of incident atherosclerotic cardiovascular disease ≥7.5%),27 to our knowledge, there are no established long‐term risk thresholds influencing secondary prevention therapy among patients with MI. Thus, once such a threshold is established for some specific treatments in the future among MI patients, TRS2°P should be tested in the context of that specific threshold.…”